Sialorrhea study (SIAXI) successfully completed.
Sialorrhea (drooling) can be a troublesome and disabling symptom resulting from various causes including Parkinson ’s disease (PD), cerebral palsy, amyotrophic lateral sclerosis (ALS) and various degenerative brain disorders. Merz completed the largest controlled study to date of incobotulinumtoxinA (Xeomin®) in the treatment of sialorrhea due to PD and other etiologies. Injection of doses of 75U and 100U of incobotulinumtoxinA (Xeomin) into the submandibular and parotid salivary glands are effective up to 16 weeks for treatment of troublesome chronic sialorrhea with more beneficial results for the 100 U treatments without meaningful added risks for adverse effects.
The study results represent an important milestone for patients suffering from Sialorrhea, as there are no approved BoNTs for this indication yet. As such, this study represents also an important milestone for Xeomin and our ongoing clinical development program SIAXI results have been accepted as „late breaking abstract”.
The first public presentation of the efficacy and safety of incobotulinumtoxinA (XEOMIN) will take place at the “International Congress of Parkinson’s Disease and Movement Disorders” which may be more familiar under the name “Movement Disorders Society” (MDS) congress. The global lead investigator Prof. A. Blitzer from New York will present the data on site in Vancouver on June 4 – 8, 2017. The fact that the abstract was accepted as late-breaking abstract underlines the interest of the scientific community in the incobotulinumtoxinA data.